Plain-English translation of NCT06461819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether men with early-stage prostate cancer can safely receive higher doses of radiation therapy when a protective substance called SPACEOAR is used. SPACEOAR is injected as a temporary spacer between the prostate and the rectum to protect the rectum from radiation damage. Researchers want to see if this approach can improve cancer control while keeping side effects low.
Higher radiation doses have been shown to reduce the chance that prostate cancer will come back, but they also increase the risk of damage to nearby organs like the bladder and rectum. This trial exists to see whether using a protective spacer allows doctors to safely deliver these higher, more effective doses while protecting healthy tissue from harm.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive an injection of the SPACEOAR protective spacer between your prostate and rectum. Then you will undergo higher-dose radiation therapy delivered in a shorter treatment schedule (hypofractionated therapy) over several weeks. The research team will monitor you during and after treatment to track how well the cancer responds and to carefully watch for any side effects from the higher radiation dose.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
South Korea